(Q34436090)

2 August 2017

title

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial (English)

1 reference

amyotrophic lateral sclerosis

2 August 2017

0 references

0 references

1 reference

1

Merit E Cudkowicz

1 reference

2 August 2017

12

David J Greenblatt

1 reference

2 August 2017

18

Ericka Simpson

1 reference

2 August 2017

Sarah Titus

2

1 reference

2 August 2017

Marianne Kearney

3

1 reference

2 August 2017

Hong Yu

4

1 reference

2 August 2017

Alexander Sherman

5

1 reference

2 August 2017

David Schoenfeld

6

1 reference

2 August 2017

Douglas Hayden

7

1 reference

2 August 2017

Amy Shui

8

1 reference

2 August 2017

Benjamin Brooks

9

1 reference

2 August 2017

Robin Conwit

10

1 reference

2 August 2017

Donna Felsenstein

11

1 reference

2 August 2017

Myles Keroack

13

1 reference

2 August 2017

John T Kissel

14

1 reference

2 August 2017

Robert Miller

15

1 reference

2 August 2017

Jeffrey Rosenfeld

16

1 reference

2 August 2017

Jeffrey D Rothstein

17

1 reference

2 August 2017

Nina Tolkoff-Rubin

19

1 reference

2 August 2017

Lorne Zinman

20

1 reference

2 August 2017

Jeremy M Shefner

21

1 reference

2 August 2017

Ceftriaxone Study Investigators

22

1 reference

2 August 2017

publication date

5 October 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

13

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1083-1091

1 reference

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Toward more efficient clinical trials for amyotrophic lateral sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Prognostic factors in ALS: A critical review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Phase II/III randomized trial of TCH346 in patients with ALS

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Shared parameter models for the joint analysis of longitudinal data and event times

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Amyotrophic lateral sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Once daily ceftriaxone for central nervous system infections and other serious pediatric infections

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Glutamate neurotoxicity and diseases of the nervous system

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Limitations of sniff nasal pressure as an outcome measurement in amyotrophic lateral sclerosis patients in a clinical trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Neuroprotective potential of ceftriaxone in in vitro models of stroke.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Amyotrophic lateral sclerosis mortality in the United States, 1979-2001.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Prognosis in amyotrophic lateral sclerosis: a population-based study.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic, protect neurons against apoptosis induced by ionizing radiation

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Antibiotic pharmacodynamics in cerebrospinal fluid

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

Application of a multidimensional caregiver burden inventory.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216315

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

27 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

Oxidant-scavenging activities of beta-lactam agents

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

The value of database controls in pilot or futility studies in ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

Guidelines for the prevention of intravascular catheter-related infections

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970222-4

7 January 2021

10.1016/S1474-4422(14)70222-4

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference